NEW YORK (GenomeWeb News) – Accuri Cytometers today said that it has raised $6 million in a Series E preferred stock financing.
The firm intends to use proceeds from the offering to support expansion of its C6 Flow Cytometer into the clinical in vitro diagnostics market. The Ann Arbor, Mich.-based firm said that it is currently implementing an ISO 13485 quality system in advance of its planned European launch of the flow cytometer with a CE-IVD Mark for clinical use. That launch would be followed by a 510(k) regulatory submission to the US Food and Drug Administration, though Accuri did not provide an estimated timeline for those efforts.
The firm recently inked a deal with IncellDx to combine its C6 Flow Cytometer with IncellDx's HPV OncoTect E6, E7 mRNA test.
"This financing round will enable us to respond to a rising number of requests for an Accuri flow cytometer for clinical diagnostic applications, providing the same benefits of high performance, cost-effectiveness and ease-of-use experienced by our life science research customers," Jeffrey Williams, president and CEO of Accuri, said in a statement.
Investors in the Series E round included Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures, and the InvestMichigan! Program co-managed by Credit Suisse.
The financing follows on last year's Series D round, which raised $4 million.